PT3008062T - Derivados de profármaco de triazolopiridinas substituídas - Google Patents

Derivados de profármaco de triazolopiridinas substituídas

Info

Publication number
PT3008062T
PT3008062T PT147289490T PT14728949T PT3008062T PT 3008062 T PT3008062 T PT 3008062T PT 147289490 T PT147289490 T PT 147289490T PT 14728949 T PT14728949 T PT 14728949T PT 3008062 T PT3008062 T PT 3008062T
Authority
PT
Portugal
Prior art keywords
prodrug derivatives
substituted triazolopyridines
triazolopyridines
substituted
prodrug
Prior art date
Application number
PT147289490T
Other languages
English (en)
Inventor
Schulze Volker
Lerchen Hans-Georg
Bierer Donald
Margret Wengner Antje
Siemeister Gerhard
Lienau Philip
Krenz Ursula
Kosemund Dirk
Stöckigt Detlef
Brüning Michael
Lücking Ulrich
Terebesi Ildikó
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PT3008062T publication Critical patent/PT3008062T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
PT147289490T 2013-06-11 2014-06-06 Derivados de profármaco de triazolopiridinas substituídas PT3008062T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11

Publications (1)

Publication Number Publication Date
PT3008062T true PT3008062T (pt) 2017-06-07

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147289490T PT3008062T (pt) 2013-06-11 2014-06-06 Derivados de profármaco de triazolopiridinas substituídas

Country Status (35)

Country Link
US (1) US9586958B2 (pt)
EP (1) EP3008062B1 (pt)
JP (1) JP2016526534A (pt)
KR (1) KR20160019492A (pt)
CN (1) CN105377848A (pt)
AP (1) AP2015008898A0 (pt)
AR (1) AR096585A1 (pt)
AU (1) AU2014280356A1 (pt)
CA (1) CA2914745A1 (pt)
CL (1) CL2015003605A1 (pt)
CR (1) CR20150659A (pt)
CU (1) CU20150176A7 (pt)
DK (1) DK3008062T3 (pt)
DO (1) DOP2015000299A (pt)
EA (1) EA201600002A1 (pt)
ES (1) ES2626790T3 (pt)
HK (1) HK1221955A1 (pt)
HR (1) HRP20170717T1 (pt)
HU (1) HUE033131T2 (pt)
IL (1) IL242847A0 (pt)
LT (1) LT3008062T (pt)
MA (1) MA38654B1 (pt)
MX (1) MX2015017119A (pt)
NI (1) NI201500176A (pt)
PE (1) PE20160156A1 (pt)
PH (1) PH12015502746A1 (pt)
PL (1) PL3008062T3 (pt)
PT (1) PT3008062T (pt)
RS (1) RS56034B1 (pt)
SG (1) SG11201509858QA (pt)
SI (1) SI3008062T1 (pt)
TN (1) TN2015000545A1 (pt)
UY (1) UY35610A (pt)
WO (1) WO2014198647A2 (pt)
ZA (1) ZA201508868B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
PT3283642T (pt) 2015-04-17 2024-01-02 Crossfire Oncology Holding B V Biomarcadores de prognóstico para quimioterapia inibidora de ttk
MX2018011831A (es) 2016-04-04 2019-02-13 Chemocentryx Inc Antagonistas solubles de receptor de c5aa(c5ar).
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
CA2291750A1 (en) 1997-05-28 1998-12-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
EP1646382A4 (en) 2003-06-30 2010-07-21 Hif Bio Inc COMPOUNDS, COMPOSITIONS AND METHODS
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
JP2009538877A (ja) 2006-05-31 2009-11-12 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピラジン化合物
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
EP2150255A4 (en) 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
CA2696200A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
SG186040A1 (en) 2007-11-27 2012-12-28 Cellzome Ltd Amino triazoles as pi3k inhibitors
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
CA2751517A1 (en) 2009-02-13 2010-08-19 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
US8729082B2 (en) 2009-04-29 2014-05-20 Bayer Intellectual Property Gmbh Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
AP3491A (en) 2011-04-21 2015-12-31 Bayer Ip Gmbh Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
PE20150354A1 (es) * 2012-07-10 2015-03-21 Bayer Pharma AG Metodos para preparar triazolopiridinas sustituidas
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
CA2914668A1 (en) * 2013-06-10 2014-12-18 Volker Schulze Novel compounds for the treatment of cancer
KR20160018534A (ko) * 2013-06-11 2016-02-17 바이엘 파마 악티엔게젤샤프트 Mps-1 키나제 억제제 및 유사분열 억제제를 포함하는 암의 치료를 위한 조합물

Also Published As

Publication number Publication date
TN2015000545A1 (en) 2017-04-06
DOP2015000299A (es) 2016-03-15
CN105377848A (zh) 2016-03-02
HRP20170717T1 (hr) 2017-07-28
EA201600002A1 (ru) 2016-06-30
MX2015017119A (es) 2016-04-06
SG11201509858QA (en) 2015-12-30
US9586958B2 (en) 2017-03-07
JP2016526534A (ja) 2016-09-05
CU20150176A7 (es) 2016-05-30
PL3008062T3 (pl) 2017-08-31
WO2014198647A3 (en) 2015-02-05
MA38654B1 (fr) 2018-11-30
SI3008062T1 (sl) 2017-06-30
NI201500176A (es) 2016-01-06
EP3008062A2 (en) 2016-04-20
KR20160019492A (ko) 2016-02-19
HUE033131T2 (en) 2017-11-28
ZA201508868B (en) 2017-08-30
PE20160156A1 (es) 2016-04-20
CL2015003605A1 (es) 2016-06-24
UY35610A (es) 2015-01-30
AR096585A1 (es) 2016-01-20
EP3008062B1 (en) 2017-04-05
CR20150659A (es) 2016-01-29
AU2014280356A1 (en) 2015-12-24
WO2014198647A2 (en) 2014-12-18
AP2015008898A0 (en) 2015-12-31
IL242847A0 (en) 2016-02-01
DK3008062T3 (en) 2017-06-12
US20160207915A1 (en) 2016-07-21
RS56034B1 (sr) 2017-09-29
LT3008062T (lt) 2017-06-12
HK1221955A1 (zh) 2017-06-16
ES2626790T3 (es) 2017-07-26
CA2914745A1 (en) 2014-12-18
PH12015502746A1 (en) 2016-03-21

Similar Documents

Publication Publication Date Title
HK1215795A1 (zh) 鵝膏毒素衍生物
SG11201506100XA (en) Pyridazinone-amides derivatives
HK1223090A1 (zh) -氮雜吲哚衍生物
HRP20181710T1 (hr) Uporaba derivata benzimidazol-prolina
LT3027598T (lt) Oksochinazolinil-butanamido dariniai
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
RS56746B1 (sr) Imidazopirazinon derivati
HK1221955A1 (zh) 取代的***並吡啶的前體藥物衍生物
HK1213566A1 (zh) 新的四唑酮衍生物
GB201314961D0 (en) Spirocyclic derivatives
GB201314965D0 (en) Spirocyclic derivatives